Remove Immune Response Remove RNA Remove Vaccine
article thumbnail

A Visual Guide to Gene Delivery

Codon

And even if all these economic hurdles are overcome, there are still three main technical challenges to solve: cargo capacity, specificity, and immune response. The human immune system is designed to recognize and eliminate foreign material, which unfortunately includes common viral vectors for gene therapy.

article thumbnail

The Long Road to End Tuberculosis

Codon

Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB. These breakthroughs have significantly curbed cases, with vaccination reducing the odds of death by 74 percent. tuberculosis , to develop the vaccine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Engineers design more powerful RNA vaccines

Science Daily: Pharmacology News

By adding synergistic self-adjuvanting properties to Covid-19 RNA vaccines, researchers showed they could significantly boost the immune response generated in mice.

RNA
article thumbnail

mRNA Therapeutics: Revolutionizing Treatment Beyond Vaccines

DrugBank

Introduction Messenger RNA (mRNA) technology has emerged as one of the most significant medical breakthroughs. The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. mRNA-based cancer vaccines represent a groundbreaking innovation in oncology.

article thumbnail

Pfizer-BioNTech reports strong immune response in animals to its COVID-19 vaccine

The Pharma Data

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Tareq Aziz Touhid. The study and the data are currently subject to peer review.

article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

article thumbnail

CureVac Touts Positive Preclinical Data for COVID-19 Vaccine | 2020-10-26

The Pharma Data

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The vaccine is currently being evaluated in phase 1 and 2 human clinical trials. Source link.